Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Inhibition of glutaminase-1 (GLS-1) hampers the proliferation of tumor cells reliant on glutamine. Known glutaminase inhibitors have potential limitations, and in vivo exposures are potentially limited due to poor physicochemical properties. We initiated a GLS-1 inhibitor discovery program focused on optimizing physicochemical and pharmacokinetic properties, and have developed a new selective inhibitor, compound 27 (IPN60090), which is currently in phase 1 clinical trials. Compound 27 attains high oral exposures in preclinical species, with strong in vivo target engagement, and should robustly inhibit glutaminase in humans.

Somatosensory evoked potential activity: a measure of interhemispheric transfer in schizophrenia?

Jones and Miller (1981) reported that schizophrenics could be distinguished from healthy controls by latency differences in their ipsilateral and contralateral somatosensory evoked potentials (SEPs), considered a measure of corpus callosum conduction time. Subsequent replication studies failed to follow the method of the original study. The present study represents a precise replication. An additional control for contamination of SEPs by an auditory stimulus generated by the vibrotactile stimulus was used. Ipsilateral SEP activity was identified but poor definition of a positive peak in the range of interest prevented measurement of peak latency. Evidence was advanced to suggest that such ipsilateral potentials result from activity at the vertex. It was concluded that this method is inappropriate for the investigation of interhemispheric transmission.